Brief: Aurinia Announces Japan Approval Of Lupkynis (Voclosporin) To Treat Lupus Nephritis
24/09/2024 13:48
Sept 24 (Reuters) - Aurinia Pharmaceuticals Inc
AUPH.O :
* AURINIA ANNOUNCES JAPAN APPROVAL OF LUPKYNIS®
(VOCLOSPORIN) TO
TREAT LUPUS NEPHRITIS
Source text for Eikon: ID:nBw2rkvvKa
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death